TY - JOUR
T1 - Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes
AU - de Ligt, Marlies
AU - Bruls, Yvonne M. H.
AU - Hansen, Jan
AU - Habets, Marie-Fleur
AU - Havekes, Bas
AU - Nascimento, Emmani B. M.
AU - Moonen-Kornips, Esther
AU - Schaart, Gert
AU - Schrauwen-Hinderling, Vera B.
AU - van Marken Lichtenbelt, Wouter
AU - Schrauwen, Patrick
PY - 2018/6
Y1 - 2018/6
N2 - OBJECTIVE: Resveratrol supplementation improves metabolic health in healthy obese men, but not in patients with type 2 diabetes (T2D) when given as add-on therapy. Therefore, we examined whether resveratrol can enhance metabolic health in men at risk of developing T2D. Additionally, we examined if resveratrol can stimulate brown adipose tissue (BAT).METHODS: Thirteen male first degree relatives (FDR) of patients with T2D received resveratrol (150 mg/day) and placebo for 30 days in a randomized, placebo controlled, cross-over trial.RESULTS: Resveratrol significantly improved ex vivo muscle mitochondrial function on a fatty acid-derived substrate. However, resveratrol did not improve insulin sensitivity, expressed as the rate of glucose disposal during a two-step hyperinsulinemic-euglycemic clamp. Also, intrahepatic and intramyocellular lipid content, substrate utilization, energy metabolism, and cold-stimulated
18F-FDG glucose uptake in BAT (n = 8) remained unaffected by resveratrol. In vitro experiments in adipocytes derived from human BAT confirmed the lack of effect on BAT.
CONCLUSIONS: Resveratrol stimulates muscle mitochondrial function in FDR males, which is in concordance with previous results. However, no other metabolic benefits of resveratrol were found in this group. This could be attributed to subject characteristics causing alterations in metabolism of resveratrol and thereby affecting resveratrol's effectiveness. CLINICALTRIALS.GOV ID: NCT02129595.
AB - OBJECTIVE: Resveratrol supplementation improves metabolic health in healthy obese men, but not in patients with type 2 diabetes (T2D) when given as add-on therapy. Therefore, we examined whether resveratrol can enhance metabolic health in men at risk of developing T2D. Additionally, we examined if resveratrol can stimulate brown adipose tissue (BAT).METHODS: Thirteen male first degree relatives (FDR) of patients with T2D received resveratrol (150 mg/day) and placebo for 30 days in a randomized, placebo controlled, cross-over trial.RESULTS: Resveratrol significantly improved ex vivo muscle mitochondrial function on a fatty acid-derived substrate. However, resveratrol did not improve insulin sensitivity, expressed as the rate of glucose disposal during a two-step hyperinsulinemic-euglycemic clamp. Also, intrahepatic and intramyocellular lipid content, substrate utilization, energy metabolism, and cold-stimulated
18F-FDG glucose uptake in BAT (n = 8) remained unaffected by resveratrol. In vitro experiments in adipocytes derived from human BAT confirmed the lack of effect on BAT.
CONCLUSIONS: Resveratrol stimulates muscle mitochondrial function in FDR males, which is in concordance with previous results. However, no other metabolic benefits of resveratrol were found in this group. This could be attributed to subject characteristics causing alterations in metabolism of resveratrol and thereby affecting resveratrol's effectiveness. CLINICALTRIALS.GOV ID: NCT02129595.
KW - Resveratrol
KW - Type 2 diabetes
KW - Pre-diabetes
KW - Insulin sensitivity
KW - Mitochondrial function
KW - Brown adipose tissue
KW - RANDOMIZED CONTROLLED-TRIAL
KW - CONTROLLED CLINICAL-TRIAL
KW - GLUCOSE-TOLERANCE
KW - METABOLIC SYNDROME
KW - LIPID-CONTENT
KW - OBESE HUMANS
KW - SUPPLEMENTATION
KW - MUSCLE
KW - MELLITUS
KW - MEN
U2 - 10.1016/j.molmet.2018.04.004
DO - 10.1016/j.molmet.2018.04.004
M3 - Article
C2 - 29706321
SN - 2212-8778
VL - 12
SP - 39
EP - 47
JO - Molecular Metabolism
JF - Molecular Metabolism
ER -